Brind.

Codexis, a biomedical and genetics company, underperformed the S&P 500 this year.

1 report, 1 independent Updated Aug 14

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Codexis

Keep exploring

The entities involved

Codexis
American protein engineering company
- Codexis advanced production with its partner/product Synthesis.Mon 11:07
- Codexis has reached an agreement to explore stereo-defined fragment synthesis as part of its advanced production strategy.Mon 11:07

Coverage

Newest first; wire copies grouped

Aug 14ZacksCodexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates Codexis (CDXS) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss